Hepatitis C hypervariable region 1: Association of reduced selection pressure in African Americans with treatment failure

Digestive Diseases and Sciences

Volumn 52, Issue 10, 2007, Pages 2540-2549

  Park, Vicki M ^a   Mason, Barbara C ^a   Krushkal, Julia ^a   Li, Rongling ^a   Riely, Caroline ^a   Fleckenstein, Jaquelyn ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

African American; Caucasian; Hepatitis C; Hypervariable region 1; Nonsynonymous substitution; Selection pressure

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS GENOME;

ADULT; AFRICAN AMERICANS; ANTIVIRAL AGENTS; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SELECTION (GENETICS); TENNESSEE; TREATMENT FAILURE; VIRAL PROTEINS;

EID: 34548503608     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9726-8     Document Type: Article

References (60)

1. Kim WR (2002) The burden of hepatitis C in the United States. Hepatology 36:S30-S34
2. Simmonds P (1995) Variability of hepatitis C virus. Hepatology 21:570-583
3. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shini T, Simmonds P, Smith D, Stuyver L, Weiner A (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143:2493-2503
4. Ina Y, Mizokami M, Ohba K, Gojobori T (1994) Reduction of synonymous substitutions in the core protein gene of hepatitis C virus. J Mol Evol 38:50-56
5. McAllister J, Casino C, Davidson F, Power J, Lawlor E, Yap PL, Simmonds P, Smith DB (1998) Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 72:4893-4905
6. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D (1998) Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 54:256-264
7. Sheridan I, Pybus OG, Holmes EC, Klenerman P (2004) High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 78:3447-3454
8. Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, Koziel MJ, Sherman KE (2005) HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 105:533-541
9. Tagariello G, Gerotto M, Pontisso P, Belvini D, Salviato R, Radossi P, Alberti A (2004) Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia. Haemophilia 10:81-86
10. Zehender G, De Maddalena C, Bernini F, Ebranati E, Monti G, Pioltelli P, Galli M (2005) Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol 79:9145-9156
11. Ray SC, Mao Q, Lanford RE, Bassett S, Laeyendecker O, Wang YM, Thomas DL (2000) Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol 74:3058-3066
12. Solmone M, Girardi E, Lalle E, Abbate I, D'Arminio Monforte A, Cozzi-Lepri A, Alessandrini A, Piscopo R, Ebo F, Cosco L, Antonucci G, Ippolito G, Capobianchi MR (2006) Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy. Antivir Ther 11:87-94
13. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93:15394-15399
14. Frasca L, Scotta C, Del Porto P, Nicosia A, Pasquazzi C, Versace I, Masci AM, Racioppi L, Piccolella E (2003) Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. Hepatology 38:653-663
15. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset F-L (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278:41624-41630
16. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195:35-41
17. Tseng CT, Klimpel GR (2002) Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195:43-49
18. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL (2005) An Interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79:8217-8229
19. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 26:6-13
20. Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, Watanabe M (2004) Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 29:89-96
21. Alfonso V, Mbayed VA, Sookoian S, Campos RH (2005) Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients. J Gen Virol 86:2781-2786
22. Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, Vinel JP, Pascal JP, Puel J, Izopet J (2000) Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 74:661-668
23. Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, Jimenez de Anta MT, Sanchez-Tapias JM, Rodes J, Saiz JC (1999) Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 29:897-903
24. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ (2005) Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41:617- 625
25. Allain JP, Dong Y, Vandamme AM, Moulton V, Salemi M (2000) Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol 74:2541-2549
26. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965
28. Pawlotsky JM (2003) Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7:45-66
29. Farci P, Purcell RH (2000) Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20:103-126
30. Boulestin A, Kamar N, Sandres-Saune K, Legrand-Abravanel F, Alric L, Vinel JP, Rostaing L, Izopet J (2006) Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Med Virol 78:365-371
31. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492
32. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432
33. Fleckenstein J (2004) Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 6:66-70
34. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39:1702- 1708
35. Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350:2265- 2271
36. Zeuzem S (2004) Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140:370-381
37. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37:1343-1350
38. Keenan ED, Rouster SD, Shire NJ, Horn PS, Sherman KE (2004) Complexity and diversity of hepatitis C virus RNA in African Americans and whites: analysis of the envelope-coding domain. J Infect Dis 190:511-514
39. Layden-Almer JE, Kuiken C, Ribeiro RM, Kunstman KJ, Perelson AS, Layden TJ, Wolinsky SM (2005) Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 192:1078-1087
40. NIH (2002) NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci State 19:1-46
41. Qiu P, Cai XY, Wang L, Greene JR, Malcolm B (2002) Hepatitis C virus whole genome position weight matrix and robust primer design. BMC Microbiol 2:29
42. Yao E, Tavis JE (2005) A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2:88
43. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT (1996) Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542
44. Kumar S, Tamura K, Nei M (2004) MEGA3: integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5:150-163
45. Nei M, Kumar S (2000) Molecular evolution and phylogenetics. Oxford University Press, New York
46. Babik JM, Holodniy M (2003) Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 77:1940-1950
47. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99:3081-3086
48. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL (1999) Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73:2938-2946
49. Durante Mangoni E, Forton DM, Ruggiero G, Karayiannis P (2003) Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J Med Virol 70:62-73
50. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM (2005) Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79:3071-3083
51. Gaudy C, Moreau A, Veillon P, Temoin S, Lunel F, Goudeau A (2003) Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome. J Clin Microbiol 41:3615-3622
52. Rodrigo AG, Mullins JI (1996) Human immunodeficiency virus type 1 molecular evolution and the measure of selection. AIDS Res Hum Retroviruses 12:1681-1685
53. Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D (1999) Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 73:6490-6499
54. Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT (2004) Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis 189:1472-1481
55. Brown RJ, Juttla VS, Tarr AW, Finnis R, Irving WL, Hemsley S, Flower DR, Borrow P, Ball JK (2005) Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol 86:1931-1942
56. Boulestin A, Sandres-Saune K, Payen JL, Alric L, Dubois M, Pasquier C, Vinel JP, Pascal JP, Puel J, Izopet J (2002) Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha. J Med Virol 68:221-228
57. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75:5703- 5710
58. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM (2003) Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 37:590-599
59. Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU (2002) First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 9:340-345
60. Pawlotsky JM (2000) Hepatitis C virus resistance to antiviral therapy. Hepatology 32:889-896